A new anti-CD22 CAR-T cell therapy in pediatric patients

<p class="article-intro">In pediatric patients with refractory/relapsed B acute lymphoblastic leukemia (B-ALL) a novel CD22-CAR-T cell immunotherapy is a highly effective and safe treatment option. </p> <hr /> <p class="article-content"><p>B acute lymphoblastic leukemia is a fatal blood cell tumor that is usually treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HCT), and CD19-CAR-T cell therapy has been successful in treating refractory or relapsed (r/r) B-ALL patients. However, some patients would become refractory to all these treatment options and relapse.&nbsp;</p> <p>In this study, the humanized CD22-CAR-T cell therapy was evaluated as a treatment option for pediatric r/r B-ALL patients who failed multiple lines of treatment including allo-HCT and CD19-CAR-T cell therapy. A lentiviral vector was generated carrying a humanized CD22-CAR-T design. CAR-T cells were infused in non transplant (8,2 &times; 10⁵/kg) and transplant patients (0,9 &times; 10⁵/kg).&nbsp;</p> <p>The treatment was highly effective with an overall response rate (ORR) of 86,7 % and complete remission (CR) rate of 80,0 % . The response cases achieved a progression-free survival (PFS) rate of 91,7 % during a median follow-up of 108 (46‑199) days. It also has excellent safety profile with minor side effects and no death.&nbsp;</p> <p>In summary, the study shows that CD22-CAR-T cell therapy is an effective and safe treatment option for pediatric r/r B-ALL patients even after they failed CD19-CAR-T therapy and allo-HCT.&nbsp;</p> <p><strong><em>Reference: </em></strong></p> <p><em>Pan J et al.: Efficacy and safety of CD22-directed CAR-T cell therapy in 15 pediatric refractory or relapsed B acute lymphoblastic leukemia patients. EHA Annual Congress, abstract # S832</em></p></p>